Honeywell Advanced Materials, a world leader in the development, manufacture and supply of refrigerants, is committed to helping customers achieve their sustainability goals. Honeywell has invested a billion dollars in research, development, and new capacity for Solstice® HFO technology to help businesses transition to lower-carbon future by converting from high global warming potential hydrofluorocarbons (HFCs) to Solstice® hydrofluoroolefin (HFO) technology.

Solstice® helps customers lower their carbon footprint and improve energy efficiency without sacrificing end-product performance. Worldwide adoption of Solstice® products has resulted in the reduction of more than 200 million metric tons of CO2 to date, equal to eliminating the emissions from more than 42 million cars.

Solstice® Air is a breakthrough medical propellant currently in clinical development for pressurized metered dose inhalers (pMDIs) with the ability to help reduce greenhouse gas emissions. A near-zero global warming potential (GWP) alternative to hydrofluoroalkanes, Solstice® Air is non-flammable (per ASTM E-681 and ISO 10156), non-ozone depleting, and VOC-exempt (U.S. EPA and CARB).

Honeywell
115 Tabor Rd
Morris Plains, NJ 07950
USA

Websitehwll.co/mdi
EmailAllan.Grossart@honeywell.com

LinkedIn logo

Honeywell at RDD Europe 2025

Navigating the Global Regulatory Landscape Enabling the Sustainability Transition in the pMDI Space
Mark Boelens, Andrew Van Deusen, Nilesh Wagh and Michiel Ullmann
Performance Comparison of Beclomethasone, Formoterol, and Glycopyrronium Solution Formulations in HFO-1234ze(E) to Reference Listed Drugs
Gregory Smith

Products and Services

↑ Back to Top